Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Mycoses 2 Leukemia 2 Invasive Fungal Infections 2 Pulmonary Aspergillosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neutropenia 1 Neoplasms 1 Leukemia, Myelomonocytic, Acute 1 Invasive Pulmonary Aspergillosis 1 Hematologic Neoplasms 1 HIV Infections 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Aspergillosis 1 Anastomotic Leak 1

Interventions

Sorafenib 222 lenvatinib 147 Bevacizumab 131 Nivolumab 87 atezolizumab 81 pembrolizumab 74 Radiosurgery 71 durvalumab 63 sintilimab 61 Oxaliplatin 60 Fluorouracil 56 Doxorubicin 47 tislelizumab 46 apatinib 45 Radiofrequency Ablation 44 Hepatectomy 43 camrelizumab 41 Leucovorin 41 Radiotherapy 40 tremelimumab 37 Magnetic Resonance Spectroscopy 36 regorafenib 34 Capecitabine 30 Immune Checkpoint Inhibitors 29 Folfox protocol 29 Cisplatin 28 cabozantinib 26 Gemcitabine 26 Cyclophosphamide 26 Ipilimumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × Amphotericin B × Clear all

NCT01686607 2024-10-21

MYCOS

Astellas Pharma Inc

40,110 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡